Eva Wagner-Drouet

1 week ago | nature.com | Ali Bazarbachi |Didier Blaise |Eva Wagner-Drouet |Jakob Passweg |Ibrahim Yakoub-Agha |Peter Dreger | +3 more

AbstractAllogeneic hematopoietic cell transplantation remains an important curative treatment for patients with acute lymphoblastic leukemia (ALL). Over time, significant progress in transplant and post-transplant care has allowed the delivery of transplant to older patients. We assessed changes over time in characteristics and outcomes in patients ≥60 years with ALL using a dataset from the EBMT registry.

Oct 24, 2024 | nature.com | Ana Alarcon Tomas |Edouard Forcade |Vladan Vucinic |Nicolaus Kröger |Lucía López Corral |Jan Vydra | +10 more

Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].

Aug 26, 2024 | nature.com | Michael Daskalakis |Ron Ram |Emma Nicholson |Eugenio Galli |Friedrich Stölzel |Wolfgang Andreas Bethge | +5 more

Since summer 2018, three CAR-T cell products have been approved by the EMA to treat aggressive B-cell lymphomas, DLBCL, either de novo or tFL and PMBCL: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) [1,2,3]. Tisa-cel, axi-cel, and liso-cel are approved for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (and primary mediastinal large B-cell lymphoma (PMBCL) for axi-cel and liso-cel).